Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F. Wang, Rui‐Hua Xu, Lin Shen et al.|Annals of Oncology|2019Cited by 475
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and BiomarkersYakun Wang, Lin Shen, Tianshu Liu et al.|The Oncologist|2022Cited by 15